An announcement from Oxford BioMedica ( (GB:OXB) ) is now available.
Oxford Biomedica PLC announced its total voting rights as of February 28, 2025, with an issued share capital consisting of 105,975,816 ordinary shares. This figure is significant for shareholders to determine their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules, impacting how they manage their investments.
More about Oxford BioMedica
OXB (LSE: OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience in viral vectors, OXB collaborates with leading pharmaceutical and biotechnology companies to provide expertise in viral vector development and manufacturing, including lentivirus and adeno-associated virus (AAV). The company offers unique technologies for viral vector manufacturing and operates facilities in the UK, France, and the US.
YTD Price Performance: -18.86%
Average Trading Volume: 6,425
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $441M
Learn more about OXB stock on TipRanks’ Stock Analysis page.